TrialIn vivo (Athens, Greece)

A Phase II Trial to Evaluate the Efficacy of Bortezomib and Liposomal Doxorubicin in Patients With BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer (KGOG 3044/EBLIN).

Yong Jae Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.